Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Response
Clin Cancer Res. 2024 Feb 1;30(3):639. doi: 10.1158/1078-0432.CCR-23-3603.NO ABSTRACTPMID:38298142 | DOI:10.1158/1078-0432.CCR-23-3603 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Ankush Bhatia Raquel Moreno Anne S Reiner Subhiksha Nandakumar Henry S Walch Rachna Malani Katherine S Panageas Ingo K Mellinghoff Tejus A Bale Robert J Young Source Type: research
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
CONCLUSIONS: Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.PMID:38300720 | DOI:10.1158/1078-0432.CCR-23-2978 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Tanya Dorff Lisa G Horvath Karen Autio Alice Bernard-Tessier Matthew B Rettig Jean-Pascal Machiels Mehmet A Bilen Martijn P Lolkema Nabil Adra Sylvie Rottey Richard Greil Nobuaki Matsubara Daniel S W Tan Alvin Wong Hiroji Uemura Charlotte Lemech Johannes Source Type: research
Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax
CONCLUSIONS: Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.PMID:38300723 | DOI:10.1158/1078-0432.CCR-23-2860 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan Jose Rodriguez-Sevilla Sangeetha Venugopal Samuel Urrutia Guillermo Montalban-Bravo Koji Sasaki Kelly S Chien Danielle Hammond Rashmi Kanagal-Shamanna Irene Ganan-Gomez Tapan M Kadia Gautam Borthakur Court Source Type: research
Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer
CONCLUSIONS: The unexpected ICB responses in patients carrying resistance biomarkers in STK11, KEAP1 and EGFR were almost exclusively observed in patients with a high TMB. Considering these alterations in the context the TMB offered a highly specific combinatorial biomarker strategy for limiting overtreatment in NSCLC.PMID:38300729 | DOI:10.1158/1078-0432.CCR-23-4027 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Joris van de Haar Joanne M Mankor Karlijn Hummelink Kim Monkhorst Egbert F Smit Lodewyk F A Wessels Edwin Cuppen Joachim G J V Aerts Emile E Voest Source Type: research
Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
CONCLUSIONS: Combining paclitaxel and carboplatin in gliomas may be more efficacious than monotherapy, as in other cancers, due to synergy and independent susceptibility to each drug. These results form the basis for an ongoing phase II trial (NCT04528680) where we investigate this combination with LIPU/MB.PMID:38295144 | DOI:10.1158/1078-0432.CCR-23-2367 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Karl J Habashy Crismita Dmello Li Chen Victor A Arrieta Kwang-Soo Kim Andrew Gould Mark W Youngblood Guillaume Bouchoux Kirsten B Bell Burdett Hui Zhang Michael Canney Roger Stupp Adam M Sonabend Source Type: research
Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma
CONCLUSIONS: We developed a targeted sequencing workflow for CSF cfDNA as well as a strategy for interpretation and reporting of sequencing results based on a molecular-guided tumor classification in glioma.PMID:38295147 | DOI:10.1158/1078-0432.CCR-23-2907 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Florian Iser Felix Hinz Dirk C Hoffmann Niklas Grassl Cansu G üngör Jochen Meyer Laura D örner Lea Hofmann Vanessa Kelbch Kirsten G öbel Mustafa Ahmed Mahmutoglu Phillipp Vollmuth Areeba Patel Duy Nguyen Leon D Kaulen Iris Mildenberger Katharina Sahm Source Type: research
Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
CONCLUSIONS: GS-3583 was relatively well tolerated and induced dose-dependent expansion of cDCs in the periphery of patients with advanced solid tumors. However, development of a second primary malignancy provides a cautionary tale for the FLT3 agonist mechanism.PMID:38295150 | DOI:10.1158/1078-0432.CCR-23-2808 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Anthony W Tolcher Joshua D Brody Nishanthan Rajakumaraswamy Michelle Kuhne Torsten Trowe Anees M Dauki Shantheri Kochikar Pai Ling Han Kai-Wen Lin Michael Petrarca Shivaani Kummar Source Type: research
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
CONCLUSION: The CPP of relatlimab alone or in combination with nivolumab supports the approved dosing in advanced melanoma and the continued evaluation of nivolumab and relatlimab across other solid tumors.PMID:38295151 | DOI:10.1158/1078-0432.CCR-23-2396 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Yue Zhao Zheyi Hu Sai Praneeth Bathena Sarah Keidel Karen Miller-Moslin Paul Statkevich Akintunde Bello Amit Roy Satyendra Suryawanshi Source Type: research
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
CONCLUSIONS: Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with GC, and no new safety signals were observed, compared with either monotherapy.PMID:38295160 | DOI:10.1158/1078-0432.CCR-23-1768 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 31, 2024 Category: Cancer & Oncology Authors: Akihito Kawazoe Noboru Yamamoto Naotoshi Sugimoto Hisato Kawakami Takashi Oshima Kensei Yamaguchi Kaori Hino Motohiro Hirao Yukinori Kurokawa Takeshi Kawakami Masahiro Tsuda Hiroki Hara Shota Kaname Daiko Matsuoka Yohei Otake Keisuke Yasuda Takao Takase S Source Type: research
IL-15 and IL-21: Better when membrane-tethered together on anti-tumor T cells
Clin Cancer Res. 2024 Jan 30. doi: 10.1158/1078-0432.CCR-23-3466. Online ahead of print.ABSTRACTSystemic administration of homeostatic gamma-chain cytokines mediates antitumor responses in some patients treated with adoptive immunotherapy. Yet many patients experience toxic side effects. New work presented herein suggests these limitations can be overcome by membrane-tethering IL-15 and IL-21 to T cell products. This finding has major implications in advancing medicine.PMID:38289325 | DOI:10.1158/1078-0432.CCR-23-3466 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 30, 2024 Category: Cancer & Oncology Authors: Ayana T Ruffin Megen C Wittling Anna C Cole Chrystal M Paulos Source Type: research
Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212)
CONCLUSIONS: Extended molecular profiling beyond RAS may have the potential to improve of the patient selection for anti-EGFR containing maintenance regimens.PMID:38289994 | DOI:10.1158/1078-0432.CCR-23-3023 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 30, 2024 Category: Cancer & Oncology Authors: Arndt Stahler Andreas J Kind Christine Sers Soulafa Mamlouk Lothar M üller Meinolf Karthaus Stefan Fr ühauf Ullrich Graeven Ludwig Fischer von Weikersthal Greta Sommerh äuser Stefan Kasper Beeke Hoppe Annika Kurreck Swantje Held Volker Heinemann David Source Type: research
Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
CONCLUSIONS: CNS PBPK modeling, in line with available clinical efficacy data, confirms the therapeutic value of intrathecal chemotherapy with antibody or small molecule drugs for treating neoplastic meningitis and warrants further clinical investigation of intrathecal antibody drugs to treat brain parenchyma tumors. Compared to intraventricular injection, intraventricular 24-h infusion may mitigate neurotoxicity while retaining potential efficacy.PMID:38289997 | DOI:10.1158/1078-0432.CCR-23-3062 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 30, 2024 Category: Cancer & Oncology Authors: Jing Li Andrew Wu Seongho Kim Source Type: research
Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
CONCLUSIONS: The frequency, distribution and clustering of immune cells relative to malignant ones can impact ICI efficacy in SqNSCLC patients. High CNV burden may contribute to the cold immune microenvironment. Soluble inflammation/immune-related proteins in the blood have the potential to monitor therapeutic benefit from ICI treatment in SqNSCLC patients.PMID:38277235 | DOI:10.1158/1078-0432.CCR-23-0251 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 26, 2024 Category: Cancer & Oncology Authors: Edwin Roger Parra Jiexin Zhang Dzifa Yawa Duose Edgar Gonzalez-Kozlova Mary W Redman Hong Chen Ganiraju C Manyam Gayatri Kumar Jianhua Zhang Xingzhi Song Rossana Lazcano Mario L Marques-Piubelli Caddie Laberiano-Fernandez Frank Rojas Baili Zhang Len Taing Source Type: research
Development of a [89Zr]Zr-labeled human antibody using a novel phage-displayed human scFv library
CONCLUSIONS: L111 Ab targets lung cancer cells in vitro and in vivo. [89Zr]Zr-DFO-L111 is a human antibody that will be evaluated in the first-in-human study of safety and PET imaging.PMID:38277241 | DOI:10.1158/1078-0432.CCR-23-3647 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 26, 2024 Category: Cancer & Oncology Authors: Abhay K Singh Calvin D Lewis Cristian A W V Boas Philipp Diebolder Prashant N Jethva Aaron Rhee Jong Hee Song Young Ah Goo Shunqiang Li Michael L Nickels Yongjian Liu Buck E Rogers Vaishali Kapoor Dennis E Hallahan Source Type: research
Dual-hit strategy for therapeutic targeting of pancreatic cancer in patient-derived xenograft tumors
CONCLUSION: This dual-hit strategy of SMO and FGFR inhibition provides a clinically-translatable approach to compromise the profound impermeability of PDAC tumors. Furthermore, clinical deployment of DW-MR imaging could fulfill the essential clinical-translational requirement for patient stratification.PMID:38270582 | DOI:10.1158/1078-0432.CCR-23-0131 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 25, 2024 Category: Cancer & Oncology Authors: Tista Roy Chaudhuri Qingxiang Lin Ewa K Stachowiak Spencer R Rosario Joseph A Spernyak Wen Wee Ma Michal K Stachowiak Michelle K Greene Gerard P Quinn Simon S McDade Martin Clynes Christopher J Scott Robert M Straubinger Source Type: research
